Therefore, the therapeutic effect of A2AR antagonists may be maximized in “inflamed” tumors characterized by infiltrating tumor-reactive T-cells that are otherwise rendered impotent by high adenosine levels in the TME. This evidence concerns the gene ADORA2A and neoplasm.